Solvay Pharmaceuticals CEO Dodd joins from Wyeth; Mahady named Wyeth pharmaceuticals president.
SOLVAY PHARMACEUTICALS CEO IS EX-WYETH EXEC DODD, who was named to head Solvay's U.S. Pharmaceuticals business Aug. 17. David Dodd, 45, was previously Wyeth-Ayerst senior VP-pharmaceutical products. He succeeds James Warren, PhD, who left Solvay in March for an academic position. Solvay Senior VP-Sales & Marketing Laurence Downey, MD, had been acting as interim CEO.
More from Archive
More from Pink Sheet
India is pressing ahead with “big shifts” in its regulatory approach for cell and gene therapies. Reduced “layers of review”, tighter internal timelines, upcoming guidelines to facilitate CGT development and reforms in the constitution of expert committees are some of the key changes.
Tracy Beth Høeg, who is reportedly re-examining Novavax’s COVID vaccine application, is the FDA rep at the CDC panel’s first meeting under the Trump Administration. She raised concerns about routine use of Jynneos for adolescents at risk of mpox and questioned how Moderna assessed efficacy of its COVID vaccines.
Cellares’ fully automated cell therapy manufacturing platform is the first system to receive an Advanced Manufacturing Technology designation from US FDA